ALS drug trial halted: safety data sought from 54 patients

NCT ID NCT06215755

Terminated Disease control Sponsor: Verge Genomics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called VRG50635 in 54 people with ALS (Lou Gehrig's disease). The main goal was to check if the drug is safe and how the body processes it. The trial was stopped early, but researchers were looking for side effects and changes in disease progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis amyotrophic lateral sclerosis type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Helsinki University Hospital

Helsinki, Uusimaa, FI-00029, Finland
Stan Cassidy Centre for Rehabilitation (Horizon NB)

Montreal, Quebec, H3A 2B4, Canada
The Neuro - Montréal Neurological Institute-Hospital

Montreal, Quebec, H3A 2B4, Canada
Turku University Hospital

Turku, Western Finland, FI-20520, Finland
UZ Leuven

Leuven, Flemish Brabant, Belgium
University Medical Center Utrecht

Utrecht, 3584 CX, Netherlands
University of Eastern Finland, Brain Research Unit

Kuopio, Eastern Finland, FI-70210, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.